Direct-to-Patient Site Performance Comparison Study

This document is a research report that presents a peer-reviewed study comparing the performance of Science 37's direct-to-patient (DTP) site against established industry benchmarks. The study was conducted in collaboration with Tufts Center for the Study of Drug Development (CSDD), which provided benchmark datasets and methodology. The report includes data from various phases of clinical trials, specifically Phases II, III, and IV, and addresses both orphan and non-orphan indications. The findings indicate that the DTP site significantly improves trial performance metrics, including trial completion rates and timeline performance, when used alongside traditional sites. Specific performance metrics, such as the time saved from first patient first visit (FPFV) to last patient first visit (LPFV) and database lock, are also discussed. The report emphasizes the importance of the DTP model in enhancing patient representation and overall study efficiency, although it notes that individual study results may vary based on multiple factors.